<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624191</url>
  </required_header>
  <id_info>
    <org_study_id>2021-3417</org_study_id>
    <nct_id>NCT04624191</nct_id>
  </id_info>
  <brief_title>Clinical Impact of HOME Oxygen SATURation Measurement (SATURHOME)</brief_title>
  <acronym>SATURHOME</acronym>
  <official_title>Clinical Impact of Home Oxygen Saturation Measurement in Patients With Interstitial Lung Disease: Quality of Live, Health Care Use, Score of Anxiety, Depression and Dyspnea and Physical Activity Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation IUCPQ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of saturometry at home is more and more widespread in patients suffering from&#xD;
      interstitial pulmonary diseases (IPD), the patients seeing it as reassurance and a concrete&#xD;
      way to follow the evolution of their disease. However, there are no studies evaluating the&#xD;
      real clinical benefit of taking saturation at home in this population. In addition, clinical&#xD;
      experience seems rather to demonstrate an increase in the anxiety level and the number of&#xD;
      clinically unnecessary consultations related to the use of this measure.&#xD;
&#xD;
      The secondary objectives are to determine the impact of this measurement on: (1) the health&#xD;
      care use (telephone calls, medical consultations and hospitalizations), (2) dyspnea score,&#xD;
      (3) the anxiety and depression score (HADS score) and (4) the physical activity level. The&#xD;
      exploratory objectives will be to determine if the measurement of saturation at home makes it&#xD;
      possible to (1) predict the occurrence of acute exacerbations of fibrosis, (2) effectively&#xD;
      predict the decline in respiratory function tests and (3) 1-year mortality. The investigator&#xD;
      will also assess whether this measure makes it possible to screen patients with oxygen&#xD;
      therapy needs at home. The investigator hypothesize that measuring oxygen saturation at home&#xD;
      will lead to a significant deterioration in quality of life, an increase in the use of health&#xD;
      care, a significant increase in the rate of anxiety and depression, dyspnea and a decrease in&#xD;
      the physical activity level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Measurement tools&#xD;
&#xD;
        1. Quality of life: King's Brief Interstitial Lung Disease&#xD;
&#xD;
        2. Anxiety and depression score: HADS score&#xD;
&#xD;
        3. Dyspnea score : UCSD questionnaire&#xD;
&#xD;
        4. Physical activity level during 7 days: MoveMonitor by McRoberts&#xD;
&#xD;
        5. Home base saturation: Nonin Ny vantagr 9590&#xD;
&#xD;
        6. Disease evolution : complete lung function (plethymography, sprimoetry, DLCO), 6-minute&#xD;
           walking test (following the ATS recommandation)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life by questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health care use (phone calls, medical consultation)</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on health car use as number and principal reason for : telephone calls, medical consultations and hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on dyspnea score with the University of California, San Diego Shortness of breath Questionnaire (UCSD) in a scale between 0 to 120 where 120 is the worst score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression score</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on anxiety and depression score with the Hospital Anxiety and Depression Scale Questionnaire (HADs) in a scale between 0 to 42, where 42 is the worst score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity level</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on physical activity level measure by accelerometer (McRoberts) and define by steps number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on energy expenditure (number of kilocalories burn by day), measure by accelerometer (McRoberts).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute exacerbation</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on predict the occurrence of acute exacerbations of fibrosis.&#xD;
Occurence: number of exacerbation of fibrosis during the year.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary function decline</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on predict the decline in respiratory function tests, principally the forced vital capacity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Impact of home base saturometry on 1-year mortality prediction</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group participants will be asked to measure their oxygen saturation on a daily basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saturation at home</intervention_name>
    <description>Clinical benefit of taking saturation at home in interstitial lung disease</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fibrosing interstitial lung disease&#xD;
&#xD;
          -  Saturation below 90% during the 6-minute walk test&#xD;
&#xD;
          -  Clinically stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Oxygen dependent at rest&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geneviève Dion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut universitaire de pneumologie et cardiologue de Québec - ULaval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geneviève Dion</last_name>
    <phone>418-656-8711</phone>
    <email>geneviève.dion@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jany Harvey, M.Sc.</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>5882</phone_ext>
    <email>jany.harvey@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève Dion, M.D. FRCPC</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>5511</phone_ext>
      <email>genevieve.dion@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jany Harvey, M.Sc.</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>5882</phone_ext>
      <email>jany.harvey@criucpq.ulaval.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Geneviève Dion</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Saturometry at home</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Heath care use</keyword>
  <keyword>Physical activity level</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

